Lorundrostat Shows Sustained Blood Pressure Reduction in Long-Term Hypertension Trial

New long-term results from the Transform-HTN open-label extension trial of lorundrostat, a drug currently under U.S. FDA review, demonstrated sustained reductions in automated office systolic blood pressure (AOSBP) in participants with uncontrolled or resistant hypertension. Presented at the American Heart Association (AHA) Scientific Sessions 2026, the data showed an average AOSBP reduction of 17.8 mmHg at Week 48 from baseline, with over half of participants achieving guideline-recommended blood pressure levels. The treatment was well-tolerated, with no new safety concerns identified. The FDA has a PDUFA target date of December 22, 2026, for lorundrostat.

Context

Lorundrostat is currently under review by the U.S. FDA, with its PDUFA target date set for December 22, 2026. The Transform-HTN trial is an open-label extension study aimed at assessing the long-term efficacy and safety of the drug. Previous studies have shown that many patients struggle to achieve target blood pressure levels despite existing treatments, highlighting the need for new options.

Why it matters

The results from the Transform-HTN trial indicate that lorundrostat may offer an effective treatment option for individuals with uncontrolled or resistant hypertension. This is significant as hypertension remains a leading risk factor for cardiovascular diseases. Effective management of blood pressure can lead to improved health outcomes and reduced healthcare costs associated with hypertension-related complications.

Implications

If approved, lorundrostat could change the treatment landscape for patients with resistant hypertension, potentially improving adherence to treatment and health outcomes. Healthcare providers may need to adjust treatment protocols to incorporate this new option. Patients currently struggling to manage their blood pressure may benefit from this advancement, leading to fewer complications associated with hypertension.

What to watch

As the FDA approaches its decision date, stakeholders will closely monitor the review process and any emerging data related to lorundrostat. Additionally, the American Heart Association's presentation of the trial results may influence public and professional perception of the drug. Updates on ongoing studies or additional data releases could also impact the drug's approval trajectory.